the endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabantendocanabinnoid系统和糖尿病u2014u2014关键的分析研究与利莫那班.pdf

Diabetology Metabolic Syndrome BioMed Central Review Open Access The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant Ada Letícia B Murro 1,2 Address: 1Disciplina de Endocrinologia, Departamento de Clínica Médica, Universidade Estadual de Campinas, Campinas, SP, Brazil and 2Disciplina de Endocrinologia, Faculdade de Ciências Médicas, R Vital Brazil, 250, Cidade Universitária Zeferino Vaz, Barão Geraldo, CEP: Campinas-SP, Brazil Email: Ada Letícia B Murro - leticiamurro@.br Published: 16 October 2009 Received: 28 April 2009 Accepted: 16 October 2009 Diabetology Metabolic Syndrome 2009, 1:18 doi:10.1186/1758-5996-1-18 This article is available from: /content/1/1/18 © 2009 Murro; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Rimonabant is the first CB1 receptor inhibitor available in the Brazilian market. This new drug has been approved for the treatment of obese or overweight patients associated with cardiovascular risk factors. In this article it is compared the effects of rimonabant treatment in obese patients with cardiovascular risk factors to usual obesity pharmacological treatment. Background Next, the effects of Rimonabant over each cardiovascular Rimonabant is th